Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies

Posted on: 18 Dec 17

Solution now features Clinical Metadata Repository to meet evolving data standards while providing seamless and more timely workflow for clients from data collection, through analysis to submission

BOSTON, December 18, 2017 – PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced its enhanced Global Data Operations (GDO) solution, with augmented processes and expertise that further bolsters its world leading clinical data services, including data management, statistical programming and biostatistics.

The enhanced offering is designed to help the biopharmaceutical industry reduce time to market and R&D costs for clinical trials, including complex multi-indication trials. PAREXEL is introducing features with its GDO offering including:

  • Clinical Metadata Repository: A new offering which provides clients with an extensive standards library to help simplify and automate the data collection and analysis process from protocol development through final study report. The Clinical Metadata Repository provides interoperability between the clinical data collected with different data standards and supports automated mapping into CDISC’s SDTM, and ADaM, effectively reducing mapping workload in data management; and
  • Adaptive Trials Offering: A comprehensive set of innovative services and technologies for the design, data management, and logistics necessary for informed planning and execution of adaptive trials. Recognized as a promising approach to create upfront efficiencies and cost savings, clients can utilize adaptive trials to reduce uncertainty when planning, better inform decision making, and reduce risks for subjects and sponsors.

PAREXEL’s GDO services are accessible as part of the Company’s full service clinical trial management and execution or on a functional outsourcing, or Functional Service Provider (FSP), basis. PAREXEL’s FSP approach allows clients to cost-effectively expand their resources to operate in a flexible model and tailored to the unique needs of each trial. The offering is also compatible with all major Electronic Data Capture (EDC) providers.

“As sources of data have increasingly become more diverse, regulatory agencies are requesting greater standardization for submissions. Further, the FDA is encouraging the adoption of alternative trial designs, including adaptive trials, as an increasingly important aspect of the drug development journey,” said Jason Martin, Corporate Vice President, Global Data Operations, PAREXEL. “With PAREXEL’s GDO offering, we are harnessing the power of more than 2,000 global experts to respond to these evolving dynamics with end-to-end, flexible solutions that meet the evolving and diverse needs of our clients, and as a result, accelerate timelines while reducing R&D costs.”

PAREXEL’s enhanced GDO offering with the new Clinical Metadata Repository is the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services and is currently available worldwide. For more information on the enhanced GDO offering please visit:

For more information:

Editor's Details

Fran Cator

Last updated on: 18/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.